Search

Displaying results 3221 - 3230 of 10000 in total
  1. Drug

    Ivacaftor

    go.drugbank.com/drugs/DB08820
    ApprovedInvestigational

    It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012[L768], and by Health Canada in late 2012. … [A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage

  2. Drug

    Milatuzumab

    go.drugbank.com/drugs/DB12943
    Investigational

    Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.

  3. Drug

    Gadopiclenol

    go.drugbank.com/drugs/DB17084
    ApprovedInvestigational

    [A254002] Gadopiclenol has high kinetic stability and a high r1 relaxivity, allowing it to be used at lower doses than classic extracellular GBCAs. … [L43817] In 2006, the use of GBCAs was associated with the development of nephrogenic systemic fibrosis (NSF), a rare disorder characterized by the thickening and hardening of skin and subcutaneous tissues

  4. Drug

    Phosphate ion

    go.drugbank.com/drugs/DB14523
    Investigational

    Mixtures: PERIOLIMEL N4-600E İNFÜZYONLUK ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ VE LİPİD EMÜLSİYONU, 1000 ML, PERIOLIMEL N4-600E İNFÜZYONLUK ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ VE LİPİD EMÜLSİYONU, 2000 ML
  5. Drug

    Remoxipride

    go.drugbank.com/drugs/DB00409
    ApprovedWithdrawn

    [A215422] It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]

  6. Drug

    Clioquinol

    go.drugbank.com/drugs/DB04815
    ApprovedVet approvedWithdrawn

    Clioquinol was withdrawn in 1983 due to neurotoxicity.

    Mixtures: LOCACORTENE VİOFORME 0,2 MG/G+30 MG/G KREM, 15 G, LOCACORTENE VİOFORME 0,2 MG/G+30 MG/G KREM, 30 G
  7. Drug

    Cyclandelate

    go.drugbank.com/drugs/DB04838
    ApprovedWithdrawn

    It may cause gastrointestinal distress and tachycardia. Cyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries.

  8. Drug

    Remimazolam

    go.drugbank.com/drugs/DB12404
    ApprovedInvestigational

    [A214852,A214857] Remimazolam was the first "soft" benzodiazepine analog to be developed[A214862] and was approved for use by the FDA in July 2020 under the brand name Byfavo.[L14722] … [L14647] Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as [remifentanil], are designed to be metabolically fragile and thus

  9. Drug

    Modified vaccinia ankara

    go.drugbank.com/drugs/DB15483
    ApprovedInvestigational

    Modified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus. Vaccines using MVA are live and non-replicating, and are produced using Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN).

  10. Drug

    Veliflapon

    go.drugbank.com/drugs/DB16346
    Investigational

    Veliflapon is under investigation in clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina).